Characterization of Immune Landscape Based on Homologous Recombination Deficiency Associated Signatures and Identification of Knockdown of <i>ERCC6L</i> to Promote Radiosensitivity in Breast Cancer
The HRD-related signatures displayed strong predictive capabilities for the prognosis in multiple datasets and the efficacy of immunotherapy and radiotherapy of breast cancer patients. Moreover, the composite indicator reflected the immune microenvironment characteristics and could be novel markers for predicting the prognosis and clinical treatment outcomes in breast cancer patients. Our experiments first elucidated the role of ERCC6L in enhancing radiation-induced DNA damage, presenting a novel target for strategies aimed at sensitizing cancer cells to radiotherapy.
Authors
- Haiting Zhou (ORCID: https://orcid.org/0000-0002-7953-7761)
- Jiahao Li (ORCID: https://orcid.org/0000-0002-4107-7720)
- Yizhi Jiang (ORCID: https://orcid.org/0000-0002-4812-2547)
- Gong Chen (ORCID: https://orcid.org/0000-0003-1092-2503)
- Junxia Liu (ORCID: https://orcid.org/0000-0002-9125-2750)
- Huihua Xiong
- Wentao Ha
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- The Journal of Gene Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/jgm.70012
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Xisike Clinical Oncology Research Foundation